FDA Commissioner Claims Resistance to Compounding Pharmacy Inspections - - BioPharm International

ADVERTISEMENT

FDA Commissioner Claims Resistance to Compounding Pharmacy Inspections



In an FDA blog, FDA Commissioner Margaret Hamburg stated that recent FDA inspections of 31 compounding pharmacies known to produce sterile drugs resulted in a discovery of inappropriate sterile-manufacturing conditions and FDA-483 observation results for all but one of the companies inspected. The companies were cited for incidents ranging from rust and mold in cleanrooms to unidentified black particles in vials of sterile product. Some of these FDA-483 notices have led to voluntary product recalls.

According to Hamburg, FDA was met with resistance from some of the pharmacies that were included in the inspections. She claims that some inspections were either delayed or inspectors were denied full access to records, thus requiring court-issued warrants. “These inspectional observations reveal that there continues to be reason for concern about sterility deficiencies and other problems in some compounding pharmacies across the country–problems that could potentially affect the health of patients. To carry out this proactive inspection effort, FDA had to shift resources from other areas, and this is not a sustainable approach for the longer term,” Hamburg stated on FDA.gov.  

Hamburg also stated that FDA is working with Congress on legislation for FDA oversight of compounding pharmacies and is evaluating the agency’s surveillance and enforcement approach.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here